These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

444 related articles for article (PubMed ID: 23953074)

  • 41. Liraglutide in oral antidiabetic drug combination therapy.
    Garber AJ
    Diabetes Obes Metab; 2012 Apr; 14 Suppl 2():13-9. PubMed ID: 22405265
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparison of liraglutide versus other incretin-related anti-hyperglycaemic agents.
    Blonde L; Montanya E
    Diabetes Obes Metab; 2012 Apr; 14 Suppl 2():20-32. PubMed ID: 22405266
    [TBL] [Abstract][Full Text] [Related]  

  • 43. In support of an early polypharmacy approach to the treatment of type 2 diabetes.
    Wright EE; Stonehouse AH; Cuddihy RM
    Diabetes Obes Metab; 2010 Nov; 12(11):929-40. PubMed ID: 20880339
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Willingness to pay for diabetes drug therapy in type 2 diabetes patients: based on LEAD clinical programme results.
    Jendle J; Torffvit O; Ridderstråle M; Ericsson Å; Nilsen B; Bøgelund M
    J Med Econ; 2012; 15 Suppl 2():1-5. PubMed ID: 22853443
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Type 2 diabetes: an expanded view of pathophysiology and therapy.
    Unger J; Parkin CG
    Postgrad Med; 2010 May; 122(3):145-57. PubMed ID: 20463424
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Managing type 2 diabetes: going beyond glycemic control.
    Stolar MW; Hoogwerf BJ; Gorshow SM; Boyle PJ; Wales DO
    J Manag Care Pharm; 2008 Jun; 14(5 Suppl B):s2-19. PubMed ID: 18597582
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Hypoglycemics for the treatment of type 2 diabetes in patients with chronic kidney disease: a focus on new agents.
    Fang V; Wazny LD; Raymond CB
    CANNT J; 2012; 22(1):30-6; quiz 37-8. PubMed ID: 22558681
    [No Abstract]   [Full Text] [Related]  

  • 48. [Management of type 2 diabetes: new or previous agents, how to choose?].
    Halimi S
    Presse Med; 2013 May; 42(5):861-70. PubMed ID: 23643613
    [TBL] [Abstract][Full Text] [Related]  

  • 49. New therapeutic horizons: mapping the future of glycemic control with incretin-based therapy.
    Campbell RK; Miller S
    Diabetes Educ; 2009; 35(5):731-4, 738-40, 742-4 passim. PubMed ID: 19783765
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Long-term Trends in Antidiabetes Drug Usage in the U.S.: Real-world Evidence in Patients Newly Diagnosed With Type 2 Diabetes.
    Montvida O; Shaw J; Atherton JJ; Stringer F; Paul SK
    Diabetes Care; 2018 Jan; 41(1):69-78. PubMed ID: 29109299
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies.
    Thrasher J
    Am J Cardiol; 2017 Jul; 120(1S):S4-S16. PubMed ID: 28606343
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Recent diabetes issues affecting the primary care clinician.
    Sando KR; Barboza J; Willis C; Taylor J
    South Med J; 2011 Jun; 104(6):456-61. PubMed ID: 21886036
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Beyond metformin: safety considerations in the decision-making process for selecting a second medication for type 2 diabetes management: reflections from a diabetes care editors' expert forum.
    Cefalu WT; Buse JB; Del Prato S; Home PD; LeRoith D; Nauck MA; Raz I; Rosenstock J; Riddle MC
    Diabetes Care; 2014 Sep; 37(9):2647-59. PubMed ID: 25147257
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes.
    Ferrannini E; DeFronzo RA
    Eur Heart J; 2015 Sep; 36(34):2288-96. PubMed ID: 26063450
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Health care provider management of patients with type 2 diabetes mellitus: analysis of trends in attitudes and practices.
    Williamson C; Glauser TA; Burton BS; Schneider D; Dubois AM; Patel D
    Postgrad Med; 2014 May; 126(3):145-60. PubMed ID: 24918800
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Third-line agent selection for patients with type 2 diabetes mellitus uncontrolled with sulfonylureas and metformin.
    Edwards KL; Alvarez C; Irons BK; Fields J
    Pharmacotherapy; 2008 Apr; 28(4):506-21. PubMed ID: 18363534
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Antidiabetic Drugs and the Kidney].
    Candido R
    G Ital Nefrol; 2016 Malattie Metaboliche e Rene; 33(S68):. PubMed ID: 27960013
    [No Abstract]   [Full Text] [Related]  

  • 58. Diabetes Update: New Pharmacotherapy for Type 2 Diabetes.
    Choby B
    FP Essent; 2017 May; 456():27-35. PubMed ID: 28530382
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Incretin agents in type 2 diabetes.
    Ross SA; Ekoé JM
    Can Fam Physician; 2010 Jul; 56(7):639-48. PubMed ID: 20631270
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Optimizing outcomes with incretin-based therapies: practical information for nurse practitioners to share with patients.
    Fleury-Milfort E
    J Am Acad Nurse Pract; 2009 Nov; 21 Suppl 1():642-50. PubMed ID: 19900195
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.